Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Durvalumab's safety and effectiveness in russian lung cancer patients

NCT ID NCT05456867

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goal is to gather real-world data to help optimize treatment for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab
What this could lead to
If successful, this study could help doctors understand how to better use durvalumab in everyday practice, potentially improving treatment plans for lung cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by real-world factors. It cannot prove cause and effect, and findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CARCINOMA)

Contacts and locations

Locations

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Grozny, Russia

  • Research Site

    Irkutsk, Russia

  • Research Site

    Khanty-Mansiysk, Russia

  • Research Site

    Kostroma, Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Murmansk, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Sochi, Russia

  • Research Site

    Surgut, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Vologda, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Yuzhno-Sakhalinsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.